Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on September 14, 2022. The report details the implementation of a reverse stock split previously approved by stockholders at a special meeting held on March 11, 2022. The company is incorporated in Delaware and its common stock trades on the OTC Markets.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split Execution: The Board of Directors approved a one-for-fifty (1-for-50) reverse split of issued and outstanding common stock.
- Effective Date: The split became effective at 4:01 p.m. Eastern Time on September 14, 2022.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on September 15, 2022, under the temporary ticker symbol "SILOD".
- Share Conversion: Every 50 shares of common stock were automatically combined into 1 share. Fractional shares were rounded up to the next whole share.
- Equity Adjustments: Proportionate adjustments were made to the exercise prices and share counts for all outstanding stock options, restricted stock units, and warrants.
Outlook, Risks, and Management Commentary
The company indicated that the "D" suffix in the ticker symbol "SILOD" will remain for 20 business days or until the company is listed on Nasdaq, whichever comes first. Upon meeting listing requirements, the symbol will revert to "SILO". No specific financial guidance or risk factors were disclosed in this specific filing beyond the mechanics of the stock split.
Key Facts for Investor Verification
- Verify the post-split share count and ownership percentage via the transfer agent.
- Confirm the adjusted exercise prices and share quantities for any held options, RSUs, or warrants.
- Monitor the ticker symbol change from "SILOD" back to "SILO" contingent on Nasdaq listing status.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.